ASH 2018 | Recent clinical trial updates for smoldering multiple myeloma
Irene Ghobrial
• 4 Dec 2018
Irene Ghobrial, MD, of the Dana-Farber Cancer Institute, Boston, MA, provides an overview of key updates in the treatment of high-risk smoldering multiple myeloma (SMM), specifically NCT02279394, NCT02916771 and GEM-CESAR (NCT02415413). Dr Ghobrial, speaking at the American Society of Hematology (ASH) 2018 Annual Meeting and Exposition in San Diego, CA, reveals the exciting data from these trials, offering a new treatment outlook for SMM, and hopes for better stratification of patients with SMM, notably with the use of genetics.
